EUCTR2010-021846-23-GB进行中（未招募）1 期
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects currently undergoing every 4 weeks scheduled assessments in the phase 3 study 20050147
- •Subjects must sign the informed consent before any study specific procedures are performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •Developed sensitivity to mammalian cell derived drug products during the 20050147 study
- •Currently receiving any unapproved investigational product other than denosumab
- •Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures
研究者
相似试验
撤回
3 期
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis10005959Postmenopausal osteoporosisNL-OMON30869Amgen62
进行中（未招募）
1 期
Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyBone metastases in subjects with advanced cancer or multiple myelomaMedDRA version: 14.0 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009374-27-GBAmgen Inc35
进行中（未招募）
不适用
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety ofDenosumab (AMG162) in the Treatment of Bone Loss in Subjects UndergoingAndrogen-Deprivation Therapy for Non-metastatic Prostate CancerBone Loss in patients undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancerMedDRA version: 9.1Level: LLTClassification code 10065687Term: Bone lossMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2008-006154-17-CZAmgen Inc803
进行中（未招募）
不适用
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab Administration in Postmenopausal Women with Low Bone DensityTreatment of postmenopausal osteoporosisMedDRA version: 17.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-001041-17-CZAmgen Inc.5,600
已完成
3 期
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancerbotziektenbone lossNL-OMON36983Amgen15